Evidence map›Paper›PMID 32719666›Full record

ArticleFrontiers in microbiology2020

Lampouguin Yenkoidiok-Douti, Gaspar E Canepa, Ana Beatriz F Barletta, Carolina Barillas-Mury

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. mBio · 2024
    Article
  4. Pfs47 as a Malaria Transmission-Blocking Vaccine Target.The American journal of tropical medicine and hygiene · 2022
    Article
  5. Article
  6. Frontiers in cellular and infection microbiology · 2022
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Lampouguin Yenkoidiok-DoutiLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Rockville, MD, United States.
Gaspar E CanepaLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Rockville, MD, United States.
Ana Beatriz F BarlettaLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Rockville, MD, United States.
Carolina Barillas-MuryLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Rockville, MD, United States.
National Institute of Allergy and Infectious Diseases · USNational Institutes of Health · US

Funding

Mosquito Immune Responses and Malaria TransmissionZIAAI000947 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BARILLAS-MURY, CAROLINA · 2009 to 2025
$26.2M
Mosquito Midgut Immune Responses &Malaria TransmissionZ01AI000947 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI BARILLAS-MURY, CAROLINA · 2004 to 2008
$1.8M
Intramural NIH HHS Z01 AI000947
6 · The paper itself

Abstract

An effective vaccine to reduce malaria transmission is central to control and ultimately achieve disease eradication. Recently, we demonstrated that antibodies targeting the

Indexed as

Anopheles gambiaemalariaP47passive immunizationPlasmodiumtransmission-blocking vaccinesVLPs

Identifiers

PMID32719666
PMCPMC7348136
OpenAlexW3038409433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.